GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » COGS-to-Revenue

Achiko AG (Achiko AG) COGS-to-Revenue : 0.00 (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Achiko AG COGS-to-Revenue?

Achiko AG's Cost of Goods Sold for the six months ended in Jun. 2022 was $0.00 Mil. Its Revenue for the six months ended in Jun. 2022 was $0.00 Mil.

Achiko AG's COGS to Revenue for the six months ended in Jun. 2022 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Achiko AG's Gross Margin % for the six months ended in Jun. 2022 was N/A%.


Achiko AG COGS-to-Revenue Historical Data

The historical data trend for Achiko AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG COGS-to-Revenue Chart

Achiko AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21
COGS-to-Revenue
- 0.96 0.85 0.63

Achiko AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
COGS-to-Revenue Get a 7-Day Free Trial 0.84 1.13 0.53 0.80 -

Achiko AG COGS-to-Revenue Calculation

Achiko AG's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.04 / 0.063
=0.63

Achiko AG's COGS to Revenue for the quarter that ended in Jun. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achiko AG  (OTCPK:ACHKF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Achiko AG's Gross Margin % for the six months ended in Jun. 2022 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Achiko AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Achiko AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Achiko AG (Achiko AG) Business Description

Traded in Other Exchanges
N/A
Address
Tessinerplatz 7, Zurich, CHE, CH-8002
Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.